The Problem of Rarity: Estimation of Prevalence in Rare Disease.
暂无分享,去创建一个
[1] Caroline Geck,et al. The World Factbook , 2017 .
[2] M. Hammer,et al. Clinical implications of SCN1A missense and truncation variants in a large Japanese cohort with Dravet syndrome , 2017, Epilepsia.
[3] I. Scheffer,et al. Mortality in Dravet syndrome , 2016, Epilepsy Research.
[4] Josemir W Sander,et al. Mortality in Dravet syndrome: A review , 2016, Epilepsy & Behavior.
[5] G. Carvill,et al. Pitfalls in genetic testing: the story of missed SCN1A mutations , 2016, Molecular genetics & genomic medicine.
[6] A. Berg,et al. Incidence of Dravet Syndrome in a US Population , 2015, Pediatric neurology briefs.
[7] T. Hallböök,et al. Dravet syndrome in Sweden: a population‐based study , 2015, Developmental medicine and child neurology.
[8] K. Nakken,et al. Prevalence and etiology of epilepsy in a Norwegian county—A population based study , 2015, Epilepsia.
[9] Allan Bayat,et al. The incidence of SCN1A‐related Dravet syndrome in Denmark is 1:22,000: A population‐based study from 2004 to 2009 , 2015, Epilepsia.
[10] E. Alpsoy,et al. Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid , 2015, Archives of Dermatological Research.
[11] J. Kleijnen,et al. A systematic review of the prevalence of Morquio A syndrome: challenges for study reporting in rare diseases , 2014, Orphanet Journal of Rare Diseases.
[12] Oriane Trouillard,et al. De novo mutations in HCN1 cause early infantile epileptic encephalopathy , 2014, Nature Genetics.
[13] Holger Lerche,et al. De novo loss-of-function mutations in CHD2 cause a fever-sensitive myoclonic epileptic encephalopathy sharing features with Dravet syndrome. , 2013, American journal of human genetics.
[14] K. Boycott,et al. Rare-disease genetics in the era of next-generation sequencing: discovery to translation , 2013, Nature Reviews Genetics.
[15] I. Scheffer,et al. SCN1A testing for epilepsy: Application in clinical practice , 2013, Epilepsia.
[16] S. Shorvon. Oxford Textbook of Epilepsy and Epileptic Seizures , 2013 .
[17] I. Scheffer. Diagnosis and long-term course of Dravet syndrome. , 2012, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[18] S. Zuberi,et al. Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. , 2012, Brain : a journal of neurology.
[19] R. Hubbard,et al. Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. , 2011, QJM : monthly journal of the Association of Physicians.
[20] Josemir W Sander,et al. Standards for epidemiologic studies and surveillance of epilepsy , 2011, Epilepsia.
[21] I. Scheffer,et al. Dravet syndrome as epileptic encephalopathy: evidence from long-term course and neuropathology , 2011, Brain : a journal of neurology.
[22] C. Dravet. The core Dravet syndrome phenotype , 2011, Epilepsia.
[23] D. Lindhout,et al. Adults with a history of possible Dravet syndrome: An illustration of the importance of analysis of the SCN1A gene , 2011, Epilepsia.
[24] H. Oguni,et al. Mortality in Dravet syndrome: Search for risk factors in Japanese patients , 2011, Epilepsia.
[25] P. Camfield,et al. Dravet syndrome and parent associations: The IDEA League experience with comorbid conditions, mortality, management, adaptation, and grief , 2011, Epilepsia.
[26] C. Dravet. Dravet syndrome history , 2011, Developmental medicine and child neurology.
[27] J. Huizer,et al. Recommendations for the development of national plans for rare diseases , 2010, Orphanet Journal of Rare Diseases.
[28] M. Ruberg,et al. Sporadic Infantile Epileptic Encephalopathy Caused by Mutations in PCDH19 Resembles Dravet Syndrome but Mainly Affects Females , 2009, PLoS genetics.
[29] O. Dulac,et al. Topiramate in the Treatment of Highly Refractory Patients with Dravet Syndrome , 2006, Neuropediatrics.
[30] C. Chiron. Stiripentol , 2005, Neurotherapeutics.
[31] P. Cras,et al. "Severe myoclonic epilepsy in infancy". Relevance for the clinician of severe epilepsy starting in infancy. , 2004, Acta neurologica Belgica.
[32] Berten Ceulemans,et al. De novo SCN1A mutations are a major cause of severe myoclonic epilepsy of infancy , 2003, Human mutation.
[33] Steven Petrou,et al. Truncation of the GABA(A)-receptor gamma2 subunit in a family with generalized epilepsy with febrile seizures plus. , 2002, American journal of human genetics.
[34] L. Lagae,et al. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. , 2001, American journal of human genetics.
[35] O. Dulac,et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial , 2000, The Lancet.
[36] Lawrence Joseph,et al. Estimating the prevalence of a rare disease: adjusted maximum likelihood , 1998 .
[37] H. Oguni,et al. Treatment of Severe Myoclonic Epilepsy in Infants with Bromide and Its Borderline Variant , 1994, Epilepsia.
[38] I. Jambaqué,et al. Early diagnosis of severe myoclonic epilepsy in infancy , 1992, Brain and Development.
[39] D. Hurst. Epidemiology of Severe Myoclonic Epilepsy of Infancy , 1990, Epilepsia.
[40] M. Bureau,et al. Epilepsie myoclonique grave de la premiere annee , 1982 .
[41] J. Borén,et al. [Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society]. , 2015, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.